Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia.
BACKGROUND
Levels of cannabinoid 1 receptor (CB1R) messenger RNA (mRNA) and protein, which are expressed most heavily in the cholecystokinin class of γ-aminobutyric acid (GABA) neurons, are lower in the dorsolateral prefrontal cortex in schizophrenia, and the magnitude of these differences is strongly correlated with that for glutamic acid decarboxylase 67 (GAD(67)) mRNA, a synthesizing enzyme for GABA. However, whether this correlation reflects a cause-effect relationship is unknown.


METHODS
Using quantitative in situ hybridization, we measured CB1R, GAD(67), and diacylglycerol lipase alpha (the synthesizing enzyme for the endocannabinoid 2-arachidonoylglycerol) mRNA levels in the medial prefrontal cortex of genetically engineered GAD(67) heterozygous (GAD(67)(+/-)), CB1R heterozygous (CB1R(+/-)), CB1R knockout (CB1R(-/-)), and matched wild-type mice.


RESULTS
In GAD(67)(+/-) mice, GAD(67) and CB1R mRNA levels were significantly reduced by 37% and 16%, respectively, relative to wild-type mice and were significantly correlated across animals (r = .61; p = .01). In contrast, GAD(67) mRNA levels were unaltered in CB1R(+/-) andCB1R(-/-) mice. Expression of diacylglycerol lipase alpha mRNA, which is not altered in schizophrenia, was also not altered in any of the genetically engineered mice.


CONCLUSIONS
The findings that reduced GAD(67) mRNA expression can induce lower CB1R mRNA expression support the hypothesis that lower cortical levels of CB1Rs in schizophrenia may partially compensate for deficient GAD(67)-mediated GABA synthesis by reducing endogenous cannabinoid suppression of GABA release.
Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Stephen M
SM
Eggan
Matthew S
MS
Lazarus
Samuel R
SR
Stoyak
David W
DW
Volk
Jill R
JR
Glausier
Z Josh
ZJ
Huang
David A
DA
Lewis
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D015870:Gene Expression / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005968:Glutamate Decarboxylase / Q000172:deficiency* / Q000235:genetics / Q000502:physiology*; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods; D008071:Lipoprotein Lipase / Q000096:biosynthesis; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D017397:Prefrontal Cortex / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D043884:Receptor, Cannabinoid, CB1 / Q000096:biosynthesis*; D012559:Schizophrenia / Q000235:genetics / Q000378:metabolism*
D012333:RNA, Messenger; D043884:Receptor, Cannabinoid, CB1; D008071:Lipoprotein Lipase; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1